From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Adverse event
Number of patients
%
Lower limb edema
5
19.2
Cough
Infections
Urticaria/rash
4
15.3
Arthritis
2
7.6
Transient creatine kinase elevation
1
3.8
Diarrhea
Thrombophlebitis
Others